MetaVia's DA-1726 Matches Retatrutide Weight Loss With Less Appetite Suppression in Preclinical Study
MTVA sits 31% above its 52-week low of $0.966.
Summary
MetaVia presented preclinical data showing DA-1726 matched retatrutide's weight loss in obese mice while suppressing appetite less and lowering glucose and lipids more, supporting a differentiated mechanism. The Phase 2 MetALD/ALD study is not targeted to begin until the second half of 2027.
Key Events · Product Development and Regulatory · MTVA
-
DA-1726 Matches Retatrutide in Mice
In diet-induced obese mice, DA-1726 cut body weight 34.2% and 41.7% at low and high doses versus 33.7% and 43.6% for retatrutide, after adjustment relative to controls.
-
Less Appetite Suppression, Same Weight Loss
DA-1726 reduced food intake by only 19.6% and 31.2% versus 36.7% and 41.4% for retatrutide, suggesting a larger share of weight loss comes from glucagon-driven energy expenditure.
-
Better Glucose and Lipid Numbers
Plasma glucose fell 43.0% and 39.2% versus 21.5% and 32.5% for retatrutide; LDL cholesterol dropped 89.9% and 88.4% versus 82.8% and 88.1%.
-
Liver FGF21 Pathway Engaged
Hepatic Fgf21 gene expression rose significantly (p<0.05), with liver FGF21 protein and circulating FGF21 up (p<0.001) at the higher dose — the mechanism the company ties to liver benefit.
Analysis · MTVA · Life Sciences
MetaVia now has a direct preclinical comparison against retatrutide, the triple agonist widely viewed as the efficacy benchmark in next-generation obesity drugs. DA-1726 delivered essentially the same weight loss (41.7% vs 43.6% at the high dose) while cutting food intake far less (31.2% vs 41.4%), which supports the company's thesis that glucagon-driven energy expenditure, not just appetite suppression, is doing the work. Stronger glucose and lipid lowering, plus a statistically significant rise in liver Fgf21, round out a differentiated story for a liver-focused metabolic asset. The caveat: this is mouse data presented at a conference, not human results, and the next real value inflection — a Phase 2 MetALD/ALD study — is not targeted to start until the second half of 2027, a long gap for a company with a going-concern warning and cash guided only into 1Q 2027.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MTVA was trading at $1.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $0.97 to $13.42. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.